论文部分内容阅读
脊髓灰质炎疫苗的免疫持久性经血清流行病学调查所得结果在不同地区很不一致.在意大利,一些随访研究表明,在13～25岁人群中脊髓灰质炎各型抗体呈阴性或低滴度水平,特别是3型抗体.作者在意大利对492名12岁健康青少年用增效脊髓灰质炎灭活疫苗(EIPV)作了加强免疫,观察其免疫原性和反应性,同时对这些青少年进行了乙型肝炎疫苗接种.在免疫前及免疫后1及9个月收集血液标本和免疫反应调查表.结果表明,加强免疫前97.1%的受试者对各型脊髓灰质炎病毒均有抵抗力(抗体滴度为1:8),1.9%无3型抗体,0.3%无2型抗体,0.6%无1型抗体.接种EIPV后98.4%的受试者抗体滴度明显上升(≥4倍),抗体几何平均滴度(GMT)也明显高于免疫前,1、2和3型抗体GMT分别为2679、2864和
Immunohistochemical serological surveys of the poliovirus vaccine have been found to be inconsistent across regions, with some follow-up studies in Italy showing negative or low-titer levels of each type of poliomyelitis antibody in the 13-25 year-old population , In particular antibody type 3. The authors in 492 12-year-old healthy adolescents in Italy with the enhanced polio inactivated vaccine (EIPV) was boosted to observe its immunogenicity and reactivity, while these young people were B Hepatitis B Vaccination Blood samples and immunologic response questionnaires were collected pre- and post-immunization at 1 and 9 months.The results showed that 97.1% of subjects were resistant to all types of poliovirus prior to booster immunization (antibodies Titers were 1: 8), 1.9% had no type 3 antibody, 0.3% did not have type 2 antibody and 0.6% did not type 1. 98.4% of the subjects had significantly increased antibody titer (≥4 fold) after inoculation of EIPV, The geometric mean titer (GMT) was also significantly higher than before immunization, and the GMTs for type 1, 2 and 3 antibodies were 2679 and 2864, respectively